Johnson & Johnson (NYSE: JNJ) has historically been a stable, dividend-paying stock with modest growth. However, recent investments in its pipeline have sparked optimism for better growth ahead. In 2025, the company reported revenue of $94.2 billion, with projections for 2026 at $100.5 billion, hinting at potential growth opportunities.

CEO Joaquin Duato anticipates double-digit growth by the end of the decade, driven largely by the company’s focus on becoming a leading cancer drugmaker. Johnson & Johnson aims to generate $50 billion from its oncology business, doubling its current revenue in that area.

While Johnson & Johnson’s stock may not be considered a bargain buy at the moment, its projected growth and solid dividend yield of 2.3% make it an attractive long-term investment option. With a PEG ratio above the typical cutoff for bargain buys, the company’s potential for future growth could drive stock value higher.

Investors looking for potential high-growth stocks may want to explore other options beyond Johnson & Johnson. While the company shows promise, there are other stocks identified by The Motley Fool Stock Advisor team that could offer substantial returns in the coming years.

The Motley Fool Stock Advisor has a history of outperforming the market, with a total average return of 906% compared to the S&P 500’s 195%. By joining Stock Advisor, investors can access the latest top 10 stock recommendations and be part of an investing community focused on individual investors.

Read more at Yahoo Finance: Johnson & Johnson’s Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?